 |
|
|
| |
Population Pharmacokinetic Analysis of Voxilaprevir, a Pangenotypic
HCV NS3/4A Protease Inhibitor in Hepatitis C Virus-Infected Subjects
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL
Brian J. Kirby,1 Erik Mogalian,1 Yuying Gao,2 Anita Mathias1
1Gilead Sciences, Inc., Foster City, California, USA; 2Certara Strategic Consulting, Menlo Park, California
|
| |
|
|
|
|
|
